Limits...
Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.

Liu W, Zhang L, Shi J, Liu Y, Zhou L, Hou K, Qu X, Teng Y - Oncol Lett (2015)

Bottom Line: The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ(2) tests, and survival functions were estimated using the Kaplan-Meier method.It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001).In addition, after a median follow-up period of 52.5 months, the patients with pAkt- and pErk1/2-negative tumors experienced a significantly longer disease-free survival (DFS) time compared with pAkt- or pErk1/2-positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)-positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

ABSTRACT

The expression of phosphorylated Akt (pAkt) and phosphorylated extracellular-regulated kinase 1/2 (pErk1/2) proteins may result in breast cancer progression and drug resistance in vitro, however, compelling evidence regarding the clinical significance of pAkt and pErk1/2 in early-stage breast cancer is currently lacking. Thus, the aim of the present study was to determine the prognostic value of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Tumor specimens were obtained from 256 patients with early-stage breast cancer who had been treated with anthracycline-based adjuvant chemotherapy, and pAkt and pErk1/2 protein expression was immunohistochemically determined. The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ(2) tests, and survival functions were estimated using the Kaplan-Meier method. It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001). In addition, after a median follow-up period of 52.5 months, the patients with pAkt- and pErk1/2-negative tumors experienced a significantly longer disease-free survival (DFS) time compared with pAkt- or pErk1/2-positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)-positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016). Thus, the coexpression of pAkt and pErk1/2 was an independent factor for a poor prognosis in early-stage and HER2-positive breast cancer patients. By contrast, pErk1/2 expression alone may be a poor predictor for determining the efficacy of anthracycline-based chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Immunohistochemical analysis, demonstrating (A) negative and (B) positive phosphorylated Akt staining; and (C) negative and (D) positive phosphorylated extracellular-regulated kinase 1/2 staining in moderately-differentiated carcinoma (magnification, ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4356398&req=5

f1-ol-09-04-1707: Immunohistochemical analysis, demonstrating (A) negative and (B) positive phosphorylated Akt staining; and (C) negative and (D) positive phosphorylated extracellular-regulated kinase 1/2 staining in moderately-differentiated carcinoma (magnification, ×400).

Mentions: pAkt and pErk1/2 protein expression levels were evaluated in 256 breast cancer tissue samples of patients with early-stage breast cancer. Prominent cytoplasmic and partial nuclear pAkt and pErk1/2 immunoreactivity was observed in the tumor cells. In total, 99 cases (38.7%) were classified as positive for pAkt expression (Fig. 1A and B) and 86 cases (33.6%) were classified as positive for pErk1/2 expression (Fig. 1C and D); thus, a significant association was observed between the expression of pAkt and pErk1/2 (Spearman rank-correlation coefficient, r=0.284; P<0.001). The expression of pAkt was significantly correlated with the occurrence of axillary lymph node metastases (P=0.020) and with the histological grade (P=0.038). However, no statistically significant correlation was identified between pAkt expression and chemotherapy resistance (P=0.313), tumor size, patient age, or ER, PR and HER2 status. Furthermore, no correlation was identified between pErk1/2 expression and a number of patient clinical characteristics, including age, tumor size, pathology, lymph node metastases, tissue grade, and ER, PR and HER2 status. However, a statistically significant difference in positive staining for pErk1/2 was observed between chemotherapy-resistant and chemotherapy-sensitive tumors (53.1 vs. 30.8%; P=0.016). The associations between pAkt/pErk1/2 expression and the conventional clinical characteristics of the patients are shown in Table I.


Clinical significance of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy.

Liu W, Zhang L, Shi J, Liu Y, Zhou L, Hou K, Qu X, Teng Y - Oncol Lett (2015)

Immunohistochemical analysis, demonstrating (A) negative and (B) positive phosphorylated Akt staining; and (C) negative and (D) positive phosphorylated extracellular-regulated kinase 1/2 staining in moderately-differentiated carcinoma (magnification, ×400).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4356398&req=5

f1-ol-09-04-1707: Immunohistochemical analysis, demonstrating (A) negative and (B) positive phosphorylated Akt staining; and (C) negative and (D) positive phosphorylated extracellular-regulated kinase 1/2 staining in moderately-differentiated carcinoma (magnification, ×400).
Mentions: pAkt and pErk1/2 protein expression levels were evaluated in 256 breast cancer tissue samples of patients with early-stage breast cancer. Prominent cytoplasmic and partial nuclear pAkt and pErk1/2 immunoreactivity was observed in the tumor cells. In total, 99 cases (38.7%) were classified as positive for pAkt expression (Fig. 1A and B) and 86 cases (33.6%) were classified as positive for pErk1/2 expression (Fig. 1C and D); thus, a significant association was observed between the expression of pAkt and pErk1/2 (Spearman rank-correlation coefficient, r=0.284; P<0.001). The expression of pAkt was significantly correlated with the occurrence of axillary lymph node metastases (P=0.020) and with the histological grade (P=0.038). However, no statistically significant correlation was identified between pAkt expression and chemotherapy resistance (P=0.313), tumor size, patient age, or ER, PR and HER2 status. Furthermore, no correlation was identified between pErk1/2 expression and a number of patient clinical characteristics, including age, tumor size, pathology, lymph node metastases, tissue grade, and ER, PR and HER2 status. However, a statistically significant difference in positive staining for pErk1/2 was observed between chemotherapy-resistant and chemotherapy-sensitive tumors (53.1 vs. 30.8%; P=0.016). The associations between pAkt/pErk1/2 expression and the conventional clinical characteristics of the patients are shown in Table I.

Bottom Line: The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ(2) tests, and survival functions were estimated using the Kaplan-Meier method.It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001).In addition, after a median follow-up period of 52.5 months, the patients with pAkt- and pErk1/2-negative tumors experienced a significantly longer disease-free survival (DFS) time compared with pAkt- or pErk1/2-positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)-positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016).

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China.

ABSTRACT

The expression of phosphorylated Akt (pAkt) and phosphorylated extracellular-regulated kinase 1/2 (pErk1/2) proteins may result in breast cancer progression and drug resistance in vitro, however, compelling evidence regarding the clinical significance of pAkt and pErk1/2 in early-stage breast cancer is currently lacking. Thus, the aim of the present study was to determine the prognostic value of pAkt and pErk1/2 expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Tumor specimens were obtained from 256 patients with early-stage breast cancer who had been treated with anthracycline-based adjuvant chemotherapy, and pAkt and pErk1/2 protein expression was immunohistochemically determined. The interactions between pAkt, pErk1/2 and clinical characteristics were assessed by performing χ(2) tests, and survival functions were estimated using the Kaplan-Meier method. It was identified that pAkt and pErk1/2 were expressed in 38.7 and 33.6% of patients, respectively, and that pAkt protein expression was correlated with pErk1/2 protein expression (P<0.001). In addition, after a median follow-up period of 52.5 months, the patients with pAkt- and pErk1/2-negative tumors experienced a significantly longer disease-free survival (DFS) time compared with pAkt- or pErk1/2-positive patients (P=0.028). pErk1/2 expression was associated with the decreased DFS time of the patients (P=0.049), and pAkt and pErk1/2 expression were associated with the decreased DFS time in human epidermal growth factor receptor (HER2)-positive patients (P=0.002). pErk1/2 expression was associated with chemotherapy resistance (P=0.016). Thus, the coexpression of pAkt and pErk1/2 was an independent factor for a poor prognosis in early-stage and HER2-positive breast cancer patients. By contrast, pErk1/2 expression alone may be a poor predictor for determining the efficacy of anthracycline-based chemotherapy.

No MeSH data available.


Related in: MedlinePlus